Ozempic Gastroparesis Settlement: Statute of Limitations for Ozempic in Washington
Latest update (2026-01)
FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Information to Targeted Concern
The legacy of general health and science information has long provided a foundation for public understanding of medical conditions and treatment options. Within this framework, discussions of pharmaceutical interventions have typically focused on therapeutic benefits and broad safety profiles. As the domain of mass production evolves, however, the focus shifts from general health education to the specific implications of widespread drug distribution and patient exposure. In this context, the transition from a general health perspective to a targeted concern about Ozempic exposure becomes relevant. The medication, originally developed for metabolic management, has been produced and prescribed at scale, leading to a growing awareness of potential adverse effects among users. One such concern is the risk of gastroparesis, a condition affecting gastric motility, which has emerged as a focal point in legal and medical discussions. For individuals in Washington who have used Ozempic and subsequently developed gastroparesis, understanding the statute of limitations is critical for pursuing settlement claims.
Understanding the Link Between Ozempic and Gastroparesis
Gastroparesis is a chronic disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or, in severe cases, surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its pharmacology involves slowing gastric emptying, which contributes to its glucose-lowering effects. However, this mechanism also underlies a range of gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these data do not explicitly list gastroparesis, the slowing of gastric emptying is a known pharmacodynamic effect of GLP-1 receptor agonists, and severe or persistent gastrointestinal symptoms may reflect underlying gastroparesis.
Mechanistic Pathway and Warning Adequacy
The mechanistic pathway linking Ozempic to gastroparesis involves the drug's action on GLP-1 receptors in the gastrointestinal tract, which inhibits gastric motility and delays gastric emptying. In susceptible individuals, this effect may become pathological, leading to symptomatic gastroparesis. The timeline between exposure and documented harm can vary; symptoms often emerge during dose escalation or after prolonged use, but cases of delayed onset have been reported. The adequacy of warnings regarding Ozempic and gastroparesis is a central issue in potential legal claims. The prescribing information for Ozempic includes warnings about serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but it does not specifically warn about gastroparesis. This gap may be relevant for patients who developed the condition and allege insufficient risk communication.
Statute of Limitations for Ozempic Claims in Washington
For affected patients in Washington, settlement-related considerations depend on the statute of limitations, which governs the time frame within which a lawsuit must be filed. In Washington, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury was discovered or reasonably should have been discovered. This 'discovery rule' means the clock starts when the patient knew or should have known that Ozempic caused their gastroparesis. Factors such as the timing of diagnosis, the onset of symptoms, and medical records documenting the link are critical. Patients who experienced gastrointestinal adverse reactions during dose escalation or after prolonged use should consult an attorney promptly to assess their claim. Settlement-related considerations also include the strength of evidence linking Ozempic to gastroparesis, the severity of the patient's condition, and the manufacturer's compliance with warning obligations. While the FDA label reports gastrointestinal adverse reactions, it does not explicitly list gastroparesis, which may support arguments that warnings were inadequate. Patients should gather medical records documenting gastroparesis diagnosis, Ozempic prescription history, and any communications with healthcare providers about symptoms. The timeline between exposure and documented harm is crucial; a shorter latency may strengthen causation, while a longer latency may complicate proof. In summary, Washington residents who developed gastroparesis after using Ozempic should be aware of the three-year statute of limitations from the date of discovery. The evidence shows a higher incidence of gastrointestinal adverse reactions with Ozempic compared to placebo, and the drug's mechanism of delaying gastric emptying provides a plausible link to gastroparesis. However, the label does not specifically warn about this condition, which may be relevant in legal claims. Patients should seek legal advice to evaluate their individual circumstances and ensure timely filing.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Ozempic gastroparesis claims in Washington?
In Washington, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury was discovered or reasonably should have been discovered. This means the clock starts when the patient knew or should have known that Ozempic caused their gastroparesis.
Does Ozempic's label warn about gastroparesis?
The prescribing information for Ozempic includes warnings about serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but it does not specifically warn about gastroparesis. This gap may be relevant for patients who developed the condition and allege insufficient risk communication.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.